Structure Therapeutics, Inc.

Organisation

601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Headquarters

Employees

Healthcare

Industry

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Price

Target

Structure Therapeutics, Inc. (GPCR) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Structure Therapeutics, Inc. (GPCR) share price will touch around $109 in next 12-months.

Currently 14 wall-street analysts regularly analyze the financials of Structure Therapeutics, Inc. on a frequent basis to provide recommendations along with target share price. 14 analysts offering 12-month price forecasts for Structure Therapeutics, Inc. (GPCR) have a share price target of $109. This median of share price forecast represents a 147.95% upside from the latest price of $43.96 as on 31.03.26.

Structure Therapeutics, Inc. (GPCR) Share Price Forecast

Home

US Stocks

Structure Therapeutics, Inc. (GPCR)

Structure Therapeutics, Inc. Stock Forecast

Structure Therapeutics, Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Structure Therapeutics, Inc. (GPCR): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Structure Therapeutics, Inc.'s share price and its median forecast price. As on 31.03.26, the difference is -65.23%

Structure Therapeutics, Inc. Forecast and Target Price

Structure Therapeutics, Inc. (GPCR) Share Price Forecast

Structure Therapeutics, Inc. (GPCR) Price vs Consensus Price Target

Structure Therapeutics, Inc. (GPCR) Share Price Forecast v/s Share Price Today

Structure Therapeutics, Inc. (GPCR): Difference between Current Price & Median Forecasted Price

Structure Therapeutics, Inc. (GPCR) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price